Published in Cancer Weekly, October 14th, 2003
The technique, called 3TP, has recently received U.S. Food and Drug Administration clearance for use in the detection of breast and prostate cancer and is slated for distribution as early as next year. It will enable doctors to distinguish between malignant tumors and benign lumps by scanning instead of cutting.
3TP (Three Time Point) makes use of existing MRI scanners, and a safe contrast agent that is injected into the patient. The suspected tumor site is scanned by MRI repeatedly over...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.